You are here

Home » Content

Methotrexate in Rheumatoid Arthritis Patients: Common Side Effects and Leading Cause of Discontinuation

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2018

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Objectives: To evaluate frequency and to identify factors which may increase the discontinuation of Methotrexate (MTX) among Rheumatoid arthritis (RA) patients in Aseer region, KSA. Methods: A cross-sectional study was conducted in Aseer Central Hospital, Southern region, Saudi Arabia that are currently or previously were using MTX. All the patients were included who fulfilled the 1987 revised American Rheumatism Association criteria for classification of RA. Medical records for 200 RA patients were chosen through convenience method then they reviewed and analyzed. Results: A total of 200 RA patients were participated, 169 (84.5%) were female and 31 (15.5%) were female. Their ages ranged from 12 to 80 years with a mean of 45.07 and standard deviation 14.37 years. About 67 (33.5%) patients told that their disease duration was 10 years and more and 147 (73.5%) patients were using MTX and 53 (26.5%) were not using the medication. Out of 147 patients, 24 (27%) of them did not take MTX regularly due to different reasons. The most common side effects were stomach ache as same as indolence and sloth. There is no statistical association between sex, education level and duration of disease and discontinuation at p=0.05. Conclusion: The study concluded a low rate of drug discontinuation due to adverse effects, MTX seems to be a safe drug for long-term use in RA patients. More attempts should be done to minimize side effects and discontinuation of MTX, in order to get the benefits of drug considered as the cornerstone in RA treatment.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-methotrexate-rheumatoid-arthritis-patients-common-side-effects-and-leading-cause-discontinuation.pdf
  • 1
116
121
  • English

REFERENCES

References: 

[1] Chen, Yen-Fu, et al. “A systematic review of the effectiveness of adalimumab, etanercept and infliximab for
the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.” Health
Technology Assessment, Vol. 10, No. 42, 2006, pp. 1-266.
[2] Van der Heijde, D.M.F.M. “Joint erosions and patients with early rheumatoid arthritis.” Rheumatology, Vol. 34.
suppl_2, 1995, pp. 74-78.
[3] Kremer, Joel M. “The changing face of therapy for rheumatoid arthritis.” Rheumatic Diseases Clinics of North
America, Vol. 21, No. 3, 1995, pp. 845-52.
[4] Kaltsonoudis, Evripidis, Charalampos Papagoras, and Alexandros A. Drosos. “Current and future role of
methotrexate in the therapeutic armamentarium for rheumatoid arthritis.” International Journal of Clinical
Rheumatology, Vol. 7, No. 2, 2012, pp. 179-89.
[5] Weinblatt, Michael E., et al. “Efficacy of low-dose methotrexate in rheumatoid arthritis.” New England Journal
of Medicine, Vol. 312, No. 13, 1985, pp. 818-22.
[6] Thompson, R.N., et al. “A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid
arthritis.” The Journal of Rheumatology 11.6 (1984): 760-763.
[7] Yazici, Y. “Long-term safety of methotrexate in the treatment of rheumatoid arthritis.” Clinical and Experimental
Rheumatology-Incl Supplements, Vol. 28, No. 5, 2010, p. S65.
[8] Singh, G., et al. “Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.” The Journal
of Rheumatology, Vol. 18, No. 2, 1991, pp. 188-94.
[9] Van Jaarsveld, C.H.M., et al. “Aggressive treatment in early rheumatoid arthritis: A randomized controlled
trial.” Annals of the Rheumatic Diseases, Vol. 59, No. 6, 2000, pp. 468-77.
[10] Blomqvist, Paul, et al. “Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.” The
Journal of Rheumatology, Vol. 27, No. 5, 2000, pp. 1171-77.
[11] Evsikova, M.D., and IuV Muraviev. “Unwanted reactions to modifying antirheumatic drugs.” Terapevticheskii
arkhiv, Vol. 77, No. 5, 2005, pp. 72-74.
[12] Pavelka, K., et al. “Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid
arthritis in the Czech and Slovak republics.” Clinical Rheumatology, Vol. 21, No. 3, 2002, pp. 220-26.
[13] Banal, Frédéric, et al. “Sensitivity and specificity of the American College of Rheumatology 1987 criteria for
the diagnosis of rheumatoid arthritis according to disease duration: A systematic literature review and metaanalysis.”
Annals of the Rheumatic Diseases, Vol. 68, No. 7, 2008, pp. 1184-91.
[14] Grove, M.L., et al. “Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice.” Qjm, Vol.
94, No. 6, 2001, pp. 309-19.
[15] El-Zorkany, Bassel K., Sherif M. Gamal, and Sherine A. El-Mofty. “Frequency and causes of discontinuation of
methotrexate in a cohort of Egyptian patients.” The Egyptian Rheumatologist, Vol. 35, No. 2, 2013, pp. 53-57.
[16] Anvari, Bita. “Leading causes of methotrexate and antimalarial drugs discontinuation in Iranian patients with
rheumatoid arthritis.” The Egyptian Rheumatologist, Vol. 38, No. 3, 2016, pp. 147-52.
[17] Attar, Suzan M. “Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based
study.” Saudi Medical Journal 31.8 (2010): 909-915.
[18] Al-Malaq, Haya M., Hussein F. Al-Arfaj, and Abdurhman S. Al-Arfaj. “Adverse drug reactions caused by
methotrexate in Saudi population.” Saudi Pharmaceutical Journal, Vol. 20, No. 4, 2012, pp. 301-05.
Alsubaie, et al. Int J Med Res Health Sci 2018, 7(1): 116-121
121
[19] Van Jaarsveld, C.H.M., et al. “Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid
arthritis.” Rheumatology, Vol. 39, No. 12, 2000, pp. 1374-82.
[20] Naranjo, Cláudio A., et al. “A method for estimating the probability of adverse drug reactions.” Clinical
Pharmacology & Therapeutics, Vol. 30, No. 2, 1981, pp. 239-45.

Thank you for copying data from http://www.arastirmax.com